Alchemab Therapeutics unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium
Cambridge, UK, June 22, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023.
ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein which is thought to have a key role in Alzheimer’s disease. Studies have found that higher expression of CD33 is associated with more advanced cognitive decline and worsening disease status – as high levels of CD33 inhibit normal function of brain-resident immune cells called microglia, which maintain neural networks and repair damage.
